{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,31]],"date-time":"2026-07-31T01:17:55Z","timestamp":1785460675260,"version":"3.56.0"},"reference-count":27,"publisher":"Wiley","issue":"7","license":[{"start":{"date-parts":[[2020,3,31]],"date-time":"2020-03-31T00:00:00Z","timestamp":1585612800000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/onlinelibrary.wiley.com\/termsAndConditions#vor"}],"content-domain":{"domain":["onlinelibrary.wiley.com"],"crossmark-restriction":true},"short-container-title":["Intl Journal of Cancer"],"published-print":{"date-parts":[[2020,10]]},"abstract":"<jats:p>Rituximab\u2010associated infusion reactions (IRs) are significant burdens on oncology patients, caregivers and healthcare providers. We evaluated whether montelukast and rupatadine improve rituximab delivery, decrease frequency\/severity of IRs and the number of medications used to control IRs. Using a nonrandomized clinical study design, we assessed adult rituximab na\u00efve patients with B\u2010cell lymphoid malignancies from January 2017 to July 2019. Prior to the first rituximab infusion patients received one of the premedication regimens: (<jats:italic>i<\/jats:italic>) standard premedications, diphenhydramine hydrochloride and acetaminophen (\u201cSP\u201d group); (<jats:italic>ii<\/jats:italic>) SP\u2009+\u2009montelukast (\u201cM\u201d group); (<jats:italic>iii<\/jats:italic>) SP\u2009+\u2009rupatadine (\u201cR\u201d group); (<jats:italic>iv<\/jats:italic>) SP\u2009+\u2009rupatadine\u2009+\u2009montelukast Schedule 1 (\u201cM\u2009+\u2009R Schedule 1\u201d group); (<jats:italic>v<\/jats:italic>) SP\u2009+\u2009rupatadine\u2009+\u2009montelukast Schedule 2 (\u201cM\u2009+\u2009R Schedule 2\u201d group). A total of 223 patients with a median age of 69\u2009years were assessed. Demographics and treatment groups were comparable among all five groups. Mean rituximab infusion time was 290\u2009min in the SP group <jats:italic>versus<\/jats:italic> 273, 261, 243 and 236\u2009min in the M, R, M\u2009+\u2009R Schedule 1 and M\u2009+\u2009R Schedule 2 groups, respectively. The incidence of rituximab IRs was 75% in the SP group <jats:italic>versus<\/jats:italic> 44, 41, 22 and 22% in the M, R, M\u2009+\u2009R Schedule 1 and M\u2009+\u2009R Schedule 2 groups, respectively. The median reaction grade was 2 in the SP group and 0 in all other groups. The median number of rescue medications was 3 in the SP group and 0 in all other groups. In conclusion, montelukast and rupatadine significantly improved rituximab delivery, decreased the rate and severity of IRs and reduced the need for rescue medications.<\/jats:p>","DOI":"10.1002\/ijc.32985","type":"journal-article","created":{"date-parts":[[2020,3,19]],"date-time":"2020-03-19T04:39:15Z","timestamp":1584592755000},"page":"1979-1986","update-policy":"https:\/\/doi.org\/10.1002\/crossmark_policy","source":"Crossref","is-referenced-by-count":12,"title":["Premedication with montelukast and rupatadine decreased rituximab infusion time, rate, severity of reactions and use of rescue medications"],"prefix":"10.1002","volume":"147","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-9851-0089","authenticated-orcid":false,"given":"Rouslan","family":"Kotchetkov","sequence":"first","affiliation":[{"name":"Simcoe Muskoka Regional Cancer Program Royal Victoria Regional Health Centre  Barrie Ontario Canada"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jesse","family":"McLean","sequence":"additional","affiliation":[{"name":"Simcoe Muskoka Regional Cancer Program Royal Victoria Regional Health Centre  Barrie Ontario Canada"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Derek","family":"Nay","sequence":"additional","affiliation":[{"name":"Simcoe Muskoka Regional Cancer Program Royal Victoria Regional Health Centre  Barrie Ontario Canada"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lauren","family":"Gerard","sequence":"additional","affiliation":[{"name":"Simcoe Muskoka Regional Cancer Program Royal Victoria Regional Health Centre  Barrie Ontario Canada"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sean","family":"Hopkins","sequence":"additional","affiliation":[{"name":"Provincial Drug Reimbursement Programs Cancer Care Ontario  Toronto Ontario Canada"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Giulio","family":"Didiodato","sequence":"additional","affiliation":[{"name":"Simcoe Muskoka Regional Cancer Program Royal Victoria Regional Health Centre  Barrie Ontario Canada"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"311","published-online":{"date-parts":[[2020,3,31]]},"reference":[{"key":"e_1_2_8_2_1","doi-asserted-by":"publisher","DOI":"10.1182\/asheducation-2007.1.233"},{"key":"e_1_2_8_3_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2004-08-3175"},{"key":"e_1_2_8_4_1","doi-asserted-by":"publisher","DOI":"10.1097\/00001813-200211002-00007"},{"key":"e_1_2_8_5_1","doi-asserted-by":"publisher","DOI":"10.1016\/S1470-2045(06)70664-7"},{"key":"e_1_2_8_6_1","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(12)61763-2"},{"key":"e_1_2_8_7_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2015-06-651125"},{"key":"e_1_2_8_8_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2015-09-667675"},{"key":"e_1_2_8_9_1","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.1999.17.6.1851"},{"key":"e_1_2_8_10_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood.V90.6.2188"},{"key":"e_1_2_8_11_1","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.1998.16.8.2825"},{"key":"e_1_2_8_12_1","doi-asserted-by":"publisher","DOI":"10.2165\/00003495-200363080-00005"},{"key":"e_1_2_8_13_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa011795"},{"key":"e_1_2_8_14_1","doi-asserted-by":"publisher","DOI":"10.1634\/theoncologist.2008-0012"},{"key":"e_1_2_8_15_1","doi-asserted-by":"publisher","DOI":"10.1186\/cc11304"},{"key":"e_1_2_8_16_1","doi-asserted-by":"publisher","DOI":"10.1007\/s00520-008-0474-5"},{"key":"e_1_2_8_17_1","unstructured":"Montelukast sodium. Product monograph Sandoz Canada Inc 2016.https:\/\/www.sandoz.ca\/sites\/www.sandoz.ca\/files\/MONTELUKAST_PM_English20160105.pdf"},{"key":"e_1_2_8_18_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood.V128.22.2142.2142"},{"key":"e_1_2_8_19_1","unstructured":"Rupatadine fumarate. Product monograph 2017.http:\/\/www.pedia-pharm.com\/wp-content\/uploads\/sites\/3\/2017\/02\/RUPALL-monograph-EN.pdf"},{"key":"e_1_2_8_20_1","doi-asserted-by":"publisher","DOI":"10.1111\/all.12531"},{"key":"e_1_2_8_21_1","unstructured":"National Cancer Institute. Common terminology criteria for adverse events (CTCAE) version 4.0.https:\/\/ctep.cancer.gov\/protocoldevelopment\/electronic_applications\/ctc.htm"},{"key":"e_1_2_8_22_1","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2013.54.8800"},{"key":"e_1_2_8_23_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2017-09-806398"},{"key":"e_1_2_8_24_1","doi-asserted-by":"publisher","DOI":"10.1111\/bjh.12102"},{"key":"e_1_2_8_25_1","unstructured":"Rituximab. Product monograph 2000.https:\/\/www.rochecanada.com\/PMs\/Rituxan\/RituxanIV_PM_E.pdf"},{"key":"e_1_2_8_26_1","doi-asserted-by":"publisher","DOI":"10.3747\/co.24.3470"},{"key":"e_1_2_8_27_1","doi-asserted-by":"publisher","DOI":"10.1002\/cncr.31706"},{"key":"e_1_2_8_28_1","first-page":"1201","article-title":"Infusion of daratumumab in combination therapies\u2014practical information for the outpatient area","volume":"143","author":"Scheid C","year":"2018","journal-title":"Dtsch Med Wochenschr"}],"container-title":["International Journal of Cancer"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.wiley.com\/onlinelibrary\/tdm\/v1\/articles\/10.1002%2Fijc.32985","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.1002\/ijc.32985","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/full-xml\/10.1002\/ijc.32985","content-type":"application\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.1002\/ijc.32985","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,9,5]],"date-time":"2023-09-05T22:38:09Z","timestamp":1693953489000},"score":1,"resource":{"primary":{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/10.1002\/ijc.32985"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,3,31]]},"references-count":27,"journal-issue":{"issue":"7","published-print":{"date-parts":[[2020,10]]}},"alternative-id":["10.1002\/ijc.32985"],"URL":"https:\/\/doi.org\/10.1002\/ijc.32985","archive":["Portico"],"relation":{},"ISSN":["0020-7136","1097-0215"],"issn-type":[{"value":"0020-7136","type":"print"},{"value":"1097-0215","type":"electronic"}],"subject":[],"published":{"date-parts":[[2020,3,31]]},"assertion":[{"value":"2020-01-14","order":0,"name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2020-03-11","order":1,"name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}},{"value":"2020-03-31","order":2,"name":"published","label":"Published","group":{"name":"publication_history","label":"Publication History"}}]}}